澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - droperidol, quantity: 2.5 mg - injection, solution - excipient ingredients: mannitol; tartaric acid; sodium hydroxide; water for injections - anaesthesia droperidol lupin injection is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia in neuroleptanalgesia in which droperidol lupin injection is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain.,psychiatry the management of severe agitation, hyperactivity, or aggressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 2277.2 mg (equivalent: gemcitabine, qty 2000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 1138.6 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 227.72 mg (equivalent: gemcitabine, qty 200 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - levetiracetam, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: glacial acetic acid; water for injections; sodium chloride; sodium acetate trihydrate - levetiracetam (film-coated tablets and oral solution) is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam sun concentrated injection after dilution is an alternative for patients when oral administration is temporarily not feasible.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - water for injections, quantity: 4.2 ml - injection - excipient ingredients: - firmagon is a gnrh receptor blocker indicated for treatment of patients with prostate cancer in whom androgen deprivation is warranted.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - water for injections, quantity: 3 ml - injection - excipient ingredients: - firmagon is a gnrh receptor blocker indicated for treatment of patients with prostate cancer in whom androgen deprivation is warranted.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 10 ml - injection, diluent for - excipient ingredients: - berinert iv is indicated for the treatment of acute attacks in patients with hereditary angioedema (hae).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sigma company limited - iron polymaltose, quantity: 318 mg (equivalent: iron, qty 100 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 8 april 2002: for the treatment of iron deficiency anaemia in the following circumstances: * when oral therapy is contraindicated. * when enteric absorption of iron is defective. * when patient non-compliance or persistent gastrointestinal intolerance makes oral therapy impractical.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - water for injections, quantity: 100 ml - injection, solution - excipient ingredients: - indications as at 11 august 2003: water for injections is used for the reconstitution and preparation of aqueous injections.